Weaver C. Barksdale & Associates’s Abiomed Inc ABMD Stock Holding History

Weaver C. Barksdale & Associates’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$3K	Sell	15 -2	-12%	-$373	﹤0.01%	436
2017 Q3	$3K	Sell	17 -4	-19%	-$605	﹤0.01%	439
2017 Q2	$3K	Hold	21	–	–	﹤0.01%	458
2017 Q1	$3K	Hold	21	–	–	﹤0.01%	462
2016 Q4	$2K	Buy	21 +5	+31%	+$579	﹤0.01%	487
2016 Q3	$2K	Hold	16	–	–	﹤0.01%	486
2016 Q2	$2K	Sell	16 -103	-87%	-$10.2K	﹤0.01%	477
2016 Q1	$11K	Buy	+119	New	+$10K	0.01%	250

Other funds holding ABMD

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Weaver C. Barksdale & Associates's ABMD Position: Q4 2017 in Review

Weaver C. Barksdale & Associates reduced its Abiomed Inc (ABMD) stake by 12% in Q4 2017, selling an estimated $373 and leaving 15 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #436.

Weaver C. Barksdale & Associates first reported a position in ABMD in Q1 2016 and has held it in 8 quarters since. The position peaked at $11K in Q1 2016. 361 funds tracked by Wall St. Rank hold ABMD as of Q4 2017.

Weaver C. Barksdale & Associates held 15 shares of Abiomed Inc worth $3K as of Q4 2017.
Weaver C. Barksdale & Associates sold 2 Abiomed Inc shares in Q4 2017, an estimated $373.
Abiomed Inc made up ﹤0.01% of Weaver C. Barksdale & Associates's portfolio in Q4 2017, its #436 holding.
Weaver C. Barksdale & Associates first reported a position in Abiomed Inc in Q1 2016 and has held it in 8 quarters since.
Weaver C. Barksdale & Associates's Abiomed Inc position peaked at $11K in Q1 2016.
361 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2017.

Based on Weaver C. Barksdale & Associates's 13F filing for Q4 2017, filed 10 Jan 2018.